Knowledge of the molecular and clonal characteristics in the myelodysplastic syndromes (MDS) and during progression to acute myeloid leukaemia (AML) is essential to understand the disease dynamics and optimize treatment. Sequencing serial bone marrow samples of eight patients, we observed that MDS featured a median of 3 mutations. Mutations in genes involved in RNA-splicing or epigenetic regulation were most frequent, and exclusively present in the major clone. Minor subclones were distinguishable in three patients. As the MDS progressed, a median of one mutation was gained, leading to clonal outgrowth. No AML developed genetically independent of a pre-existing clone. The gained mutation mostly affected genes encoding signalling proteins. Additional acquisition of genomic aberrations frequently occurred. Upon treatment, emergence of new clones could be observed. As confirmed by single-cell sequencing, multiple mutations in identical genes in different clones were present within individual patients. DNA-methylation profiling in patients without identification of novel mutations in AML revealed methylation changes in individual genes. In conclusion, our data complement previous observations on the mutational and clonal characteristics in MDS and at progression. Moreover, DNA-methylation changes may be associated with progression in single patients. Redundancy of mutated genes in different clones suggests fertile grounds promoting clonal selection or acquisition.
Summary
Knowledge of the molecular and clonal characteristics in the myelodysplastic syndromes (MDS) and during progression to acute myeloid leukaemia (AML) is essential to understand the disease dynamics and optimize treatment. Sequencing serial bone marrow samples of eight patients, we observed that MDS featured a median of 3 mutations. Mutations in genes involved in RNA-splicing or epigenetic regulation were most frequent, and exclusively present in the major clone. Minor subclones were distinguishable in three patients. As the MDS progressed, a median of one mutation was gained, leading to clonal outgrowth. No AML developed genetically independent of a pre-existing clone. The gained mutation mostly affected genes encoding signalling proteins. Additional acquisition of genomic aberrations frequently occurred. Upon treatment, emergence of new clones could be observed. As confirmed by single-cell sequencing, multiple mutations in identical genes in different clones were present within individual patients. DNA-methylation profiling in patients without identification of novel mutations in AML revealed methylation changes in individual genes. In conclusion, our data complement previous observations on the mutational and clonal characteristics in MDS and at progression. Moreover, DNA-methylation changes may be associated with progression in single patients. Redundancy of mutated genes in different clones suggests fertile grounds promoting clonal selection or acquisition.
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Myelodysplastic syndromes (MDS) progress to acute myeloid leukaemia (AML) in approximately one-third of patients (Greenberg et al, 1997 (Greenberg et al, , 2012 Nachtkamp et al, 2016) . These patients have a dismal prognosis, characterized by poor response rates to standard induction therapy and a median overall survival (OS) of less than 1 year (Stone et al, 2015; Renaud et al, 2016) .
MDS is characterized by frequent mutations in genes involved in RNA splicing (e.g. SF3B1, SRSF2, U2AF1, ZRSR2; approximately 40-60% of patients), DNA methylation (i.e. DNMT3A, TET2, IDH1, IDH2; approximately 30-40%) or chromatin remodelling (i.e. ASXL1, EZH2; approximately 15-25%) (Bejar et al, 2012; Papaemmanuil et al, 2013) . In particular, mutations in RNA splicing factors and in TET2, DNMT3A, ASXL1 or EZH2 occur early in disease evolution (Papaemmanuil et al, 2013; Mossner et al, 2016) . Cytogenetic aberrations, mutations in signalling molecules (e.g. FLT3, PTPN11, NRAS, KRAS, CBL, NF1) as well as in IDH1, IDH2 or, in certain cases, in transcription factors (e.g. RUNX1, WT1, GATA2, ETV6) rather occur at advanced MDS stages or progression to AML (Badar et al, 2015; Mossner et al, 2016; Makishima et al, 2017; da Silva-Coelho et al, 2017) .
Due to the sequential gain of mutations, subclones emerge from an ancestral clone, leading to oligoclonality and progression of the disease (Walter et al, 2012 (Walter et al, , 2013 Papaemmanuil et al, 2013; Mossner et al, 2016; Makishima et al, 2017; da Silva-Coelho et al, 2017) . If a mutation occurring in the major clone confers a sufficiently strong selective growth advantage, then the arising subclone can overgrow its ancestral clone and become the major clone (linear evolution). In contrast, with branching evolution, different subclones, each characterized by distinct mutations in addition to a set of mutations that are similar among the clones, co-exist or compete with each other until one may eventually overgrow the others (clone sweeping). Insights into the clonal architecture can be derived from next generation sequencing (NGS) analyses of the entirety of malignant cells (bulk) and be substantially complemented by analyses of single cells (Klco et al, 2014; Paguirigan et al, 2015; Niem€ oller et al, 2016; Papaemmanuil et al, 2016; Riba et al, 2016; da Silva-Coelho et al, 2017) .
Apart from genetic aberrations, DNA methylation patterns have been associated with the progression of MDS. Patients with MDS and an excess of blasts had significantly higher levels of bone marrow (BM) DNA methylation and elevated numbers (as compared to healthy controls) of aberrantly methylated CpG sites than patients with lower risk MDS (Jiang et al, 2009) . In agreement with these findings, DNA hypomethylating agents [HMAs, i.e. azacitidine or decitabine (DAC)], which have become the standard of care in the treatment of unfit MDS and AML patients, show a particularly good efficacy among patients with MDS and higher blast counts (Fenaux et al, 2010; L€ ubbert et al, 2011; Kantarjian et al, 2012; Becker et al, 2015; Dombret & Gardin, 2016) .
A thorough understanding of the genetic and epigenetic characteristics of MDS and their changes during progression to AML provides the possibility of recognizing clinical progression earlier and initiating therapeutic interventions. It also gives us a better biological understanding of the development of AML in patients with MDS, as well as in those without a prior myeloid neoplasm. The latter is particularly true for patients with clonal haematopoiesis of indeterminate potential (CHIP) or clonal cytopenia of undetermined significance (CCUS), who most frequently harbour mutations in similar genes (e.g. ASXL1, TET2, DNMT3A) as MDS patients (Kwok et al, 2015; Steensma et al, 2015; Mossner et al, 2016) .
In this study, we characterized genetic aberrations and pertinent clonal architectures in MDS and how they changed during progression to AML and under treatment using genetic analyses of bulk BM samples, as well as single cells, from a carefully selected group of patients. DNA methylation was additionally profiled in patients with distinct genetic patterns.
Patients and methods

Patient samples
We analysed mononuclear cells (MNCs) in 21 BM samples from 8 patients with MDS and progression to AML (Table I ). The samples had been collected at time of diagnosis of MDS (n = 7) or during MDS (n = 1), at AML diagnosis and, in three patients, additionally under treatment. CD3 
Sequencing and array analyses
NA libraries were prepared using customized HaloPlex assays (Agilent, Santa Clara, CA, USA; Table S1 ), and sequenced on a MiSeq instrument (Illumina, San Diego, CA, USA). Data were analysed as previously described , except that a variant allele frequency (VAF) of ≥5% was used as threshold for calling of single nucleotide variants. Potentially pathogenic variants were verified by orthogonal methods in BM and CD3 + cells. The mean NGS coverage for verified variants across all samples was 1098x (range, 53-3559x) . Cytogenetic information in addition to routine metaphase karyotyping was retrieved from CytoScan 750K Array (Affymetrix, Santa Clara, CA, USA) analyses in unsorted BM MNCs. The array data were analysed restricted to genes included in the NGS panel. Aberrations were categorized as copy number variations (CNV), i.e. gain, loss or loss of heterozygosity (LOH), or copy-neutral LOH (CN-LOH).
Single-cell genetic analysis
Single cells were isolated using a single-cell printer (SCP), as previously described (Riba et al, 2016) . After cell lysis and whole genome amplification (WGA), single-cell DNA was examined for the variants detected by NGS in the bulk samples Riba et al, 2016) . To control for allele dropouts (ADO) induced by WGA, a single nucleotide polymorphism (SNP), which was heterozygous in the bulk and located in close genomic proximity to the mutation site, was studied in parallel Riba et al, 2016) .
Derivation of clonal architecture and patterns of evolution
Clonal patterns were deduced from NGS or single-cell data. Subclones were defined as descendants from a (Bennett et al, 1982) ; IPSS-R, Revised International Prognostic Scoring System (Greenberg et al, 2012) ; m, male; MD-CMML, myelodysplastic chronic myelomonocytic leukaemia; MDS-EB1/2, myelodysplastic syndrome with excess blasts type 1/2; MDS-MLD, MDS with multilineage dysplasia; MDS, myelodysplastic syndrome; P, patient; RA, refractory anaemia; RAEB, refractory anaemia with excess blasts; TP, time point; WHO 16, classification by the World Health Organization (Arber et al, 2016 common ancestral clone (Bochtler et al, 2013) . Considering the NGS data, a variant A was assumed to have been acquired earlier during disease than a variant B, when variant A but not B was detected at an earlier time point, or, restricted to time point 1, when variant A had a VAF ≥10% higher than variant B. For the latter, VAFs were corrected for hemi-/homozygosity due to X chromosomal location in male patients or co-occurring CNV or CN-LOH. Mutation sites without detection of a CNV or CN-LOH (due to absence or limited array sensitivity) were considered to be heterozygous. Clonal architecture was derived from the deduced sequence of variant acquisition. The size of a clone was determined through the VAFs of the mutations harboured. Regarding the single-cell data, cells were combined into a single clone based on the variants identified in these cells. If only one of the co-occurring variants was detected in a cell while ADO of the other was excluded, then this variant was judged to have been acquired earlier.
DNA methylation and RNA expression analyses DNA methylation was profiled using Infinium HumanMethylation450 BeadChips (Illumina). Data were analysed using the Bioconductor/R minfi and DMRforPairs packages (Aryee et al, 2014; Rijlaarsdam et al, 2014) . Regions were set to contain at least three probes, with a maximum distance of 300 bp between individual probes (n = 52540). mRNA expression was assessed using quantitative real-time polymerase chain reaction (qPCR).
Detailed descriptions of the methods are provided in the supplemental material.
Results
Genetic aberrations in MDS
Panel sequencing among the 8 MDS patients identified a median of 182 (range, 176-232) variants per sample. After filtering by predefined criteria and validation by orthogonal methods, a median of 3 variants (range, 1-6) per sample were considered to be pathogenic (Fig 1, Table S2 ).
Six of eight patients presented with mutations in genes involved in RNA splicing (SF3B1, SRSF2, ZRSR2, U2AF1) or epigenetic regulation (TET2, IDH1, DNMT3A, ASXL1, EZH2) (Fig 1) . Mutations in transcription factors (CEBPA, RUNX1, WT1) were observed in four patients. Two patients harboured mutations in genes encoding signalling proteins (FLT3, NRAS, PTEN) (Fig 1) .
In the array analyses, the only gene mutation affected by a genomic aberration was the TET2 mutation in Patient 3 (CN-LOH 4q), in accordance with the VAF of 74% (Fig 1) . Unmutated genes affected by CNVs were KIT (gain 4q12) in Patient 3 and KMT2A (MLL; gain 11q23) in Patient 4 (Table S3 ).
Clonal architecture of MDS
Based on the mutation data, we derived information on the clonal architecture at MDS. All but one patient had an oligoclonal disease (i.e. more than one mutation could be detected). In three patients (Patients 1, 3 and 8), distinct subclones could be distinguished from an ancestral clone (Figs 1-2, Figure S1 ).
A single founder mutation could be identified in only two patients (Patients 4 and 8) (Figs 1-2, Figure S1 ). In the remaining patients, the VAFs of the mutations were too close to each other to discriminate a founder mutation. However, in these patients the ancestral clones always contained at least one mutation in a gene involved in RNA splicing or epigenetic regulation.
Mutation changes as patients progressed towards AML
At the time of AML diagnosis, a median of 191 (range, 173-254) variants were identified per sample. This translated into a median of 4 pathogenic variants (range, 1-6) per sample (Fig 1, Table S2 ).
In five of eight patients, MDS progression was associated with the acquisition of a mutation in a gene encoding a signalling protein (CSF3R, KRAS, FLT3, NRAS) (Fig 1) . Of the remaining three patients, one had gained an IDH1 mutation (Patient 7) and two had no additional mutations in comparison to the MDS time points (Patients 4 and 6). However, one of these two patients already harboured a FLT3-internal tandem duplication (ITD) during MDS (Patient 6).
Three patients additionally acquired potentially relevant genomic aberrations, i.e. CN-LOH affecting mutated genes and/or CNVs (Fig 1, Table S3 ). Patient 1 gained a CN-LOH 19q, which led to homozygosity of the initially heterozygous CEBPA mutation. Patient 3, who had a CN-LOH 4q and a gain 4q12 during MDS, had acquired a trisomy 4 at AML, which remained undetected by metaphase karyotyping at that time but was confirmed later during the disease course. Patient 5 had acquired CNVs affecting KIT (loss 4q12) and BCOR (loss Xp11).
Changes in the clonal architecture as patients progressed towards AML
Gain of a mutation between MDS and AML was associated with outgrowth of the affected clone (Fig 2) . For example, in Patient 1, outgrowth was associated with the acquisition of a CSF3R mutation; in Patient 3, the gain of a FLT3-tyrosine kinase domain (TKD) mutation led to a growth advantage of a pre-existing RUNX1 p.S141fs mutated clone, while two out of three co-existing RUNX1 mutated clones were no longer detectable.
In one patient (Patient 8), the mutations that were additionally acquired between MDS and AML probably did not contribute to the outgrowth of the clone present at MDS.
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This patient had an MDS clone with mutations in NRAS and WT1, and the AML developed from this clone, directly and without apparent gain of further mutations, while the additionally gained mutations (again in NRAS and WT1) gave rise to an additional subclone. This sample was further investigated via single-cell analyses (see below). Arrows indicate the latency in months between the MDS and subsequent sampling time points. A blue 'X' indicates genes located on the X chromosome in a male patient. Asterisks mark the sampling time points at which the specified CNVs were detected. The VAF is displayed on the yaxis. AML, acute myeloid leukaemia; CMML, chronic myelomonocytic leukaemia; MDS, myelodysplastic syndrome; MDS-EB, MDS with excess blasts; MDS-MLD, MDS with multilineage dysplasia; VAF, variant allele frequency.
MDS-EB2 AML
Patients in whom the AML directly arose from the MDS clone, i.e. without gain of additional mutations in this clone (Patients 4, 6 and 8), were apparent by the short time period (3-5 months) between diagnosis of MDS and progression to AML, compared to the remaining patients with a time to AML of 11-100 months.
Changes in the clonal architecture under treatment
For three patients, samples were available at time points during treatment (Fig 1) .
Patient 7 received lenalidomide for a del(5q) MDS. Nine months after treatment start, the pre-existing EZH2 and SF3B1 mutated clone had decreased (VAF change from 32% to 14% and 26% to 18%, respectively). The proportion of del(5q) positive cells detected by fluorescence in situ hybridization (FISH) concordantly declined, from 48/100 to 28/100. Treatment was discontinued 12 months after initiation because of a recurrence of transfusion dependency. Five months after treatment discontinuation, transformation to AML was confirmed by BM examination. At that time, an IDH1 mutation had been gained, the EZH2 and SF3B1 VAFs had increased to 46% and 48%, respectively, and the del(5q) was detectable in each of 22 metaphases counted (Fig 1,  Table I ).
Patient 3 received AML treatment with DAC and alltrans-retinoic acid (ATRA) (Clinicaltrials.gov: NCT00867672) (L€ ubbert et al, 2016) . Treatment had no immediate effect on the clonal composition, as the size of the RUNX1 p.S141fs and FLT3-TKD mutated clone remained unchanged at day 15. When BM was evaluated after six treatment courses, the size of this clone had decreased (VAF change from 43% to 29% and 47% to 32%, respectively). However, this was accompanied by outgrowth of a RUNX1 p.P57fs clone, probably due to a newly acquired FLT3-ITD. Shortly thereafter, the patient developed hyperleucocytosis and died. Patient 4 received induction and consolidation therapy for the AML. After completion, residual MDS features remained present in the BM (i.e. MDS-MLD). At that time a previously undetected DNMT3A mutated clone became evident, in addition to the pre-existing STAG2 mutated clone that had decreased to subclonal levels (VAF change from 97% to 2%). Eight months later the MDS again progressed to AML due to outgrowth of the STAG2 mutated clone after acquisition of a PHF6 mutation; the DNMT3A mutated clone became undetectable.
Occurrence of multiple mutations in identical genes
The presence of multiple mutations within the same gene was observed in three patients (Patients 1, 3 and 8) during MDS and/or AML (Fig 1) . The occurrence of additional mutations in the exact same genes may suggest the presence of a fertile ground that induces or selects clones with mutations in specific genes. in order to assess the presence of p.A314fs, which was the variant with the lowest variant allele frequency in the acute myeloid leukaemia (AML) bulk sample. A total of 42 of the 72 cells were analysed for mutations in WT1 exon 9 (containing p.K399fs) and NRAS exon 2 (p.G13D) and 3 (p.Q61K). Each column represents one single cell. Red, mutated; green, wildtype; grey, inconclusive; white, not determined. (B) Ancestral tree derived from the single-cell sequencing data. The myelodysplastic syndrome (MDS) ancestral clone is depicted in orange and subclones are depicted in blue or, if detected at the AML time point, in red. The ancestral clone gave rise to at least two different subclones, each characterized by acquisition of a distinct WT1 mutation. One AML clone emerged independently (depicted by a dotted arrow), carrying mutations in NRAS and WT1, which were different from those of the other clones.
Patient 1 harboured two TET2 mutations at MDS that were carried forward into AML. Patient 3 had four RUNX1 mutations at MDS, two of which (p.S141fs and p.P57fs) remained detectable during AML, and also acquired two different mutations in FLT3.
Patient 8 had only single mutations in NRAS and WT1 detectable at MDS, but then gained further mutations in these genes on the way to AML. The sequencing data suggested that NRAS p.G13D was the founder mutation which, in collaboration with the WT1 p.K399fs mutation, led to AML, while the additionally acquired NRAS p.Q61K and WT1 p.A314fs mutations independently emerged in a separate subclone. In order to verify these conclusions, we analysed 72 singularized BM cells from the AML diagnosis for co-occurrence of the mutations (Fig 3, Figure S2 ).
In the single-cell analyses, NRAS p.G13D occurred either alone (13 mutated cells of 42 cells analysed) or in combination with WT1 p.K399fs (6/42), while NRAS p.Q61K co-occurred with WT1 p.A314fs (3/42). No cell with both NRAS or both WT1 mutations was identified. These findings confirmed our above NGS-based conclusions on the clonal architecture. The analyses, however, revealed two further mutations in WT1 exon 7 that were not initially recognized in the NGS of the cell bulk samples due to the applied filtering steps, but were confirmed retrospectively by manual inspection of the sequencing reads ( Figure S2 ). Of these two mutations, WT1 p.S313fs was present at MDS and AML, and co-occurred in the single cell analyses with NRAS p.G13D. The other mutation was an alternative nucleotide variant encoding for WT1 p.A314fs (c.940delG), which was present only at AML and co-occurred with NRAS p.Q61K in the single cell analyses. The WT1 exon 7 variants were not detected in any other of the patients' samples analysed via NGS or in additionally analysed single cells of the Kasumi-1 cell line, indicating that these variants were not sequencing artefacts ( Figure S2 ). The combined cell bulk and single-cell data were used to derive the clonal architecture at onset of AML (Fig 3) .
Changes in DNA methylation as patients progressed towards AML DNA methylation profiles were compared between the MDS and the corresponding AML sample among patients, in whom the progression of the MDS could not be assigned to the acquisition of a new mutation (Patients 4 and 6) or to the acquisition of a new mutation in a previously unmutated gene (Patient 8).
All samples showed a high signal to noise ratio (P < 0Á001) indicating high data quality (Fig 4) . Based on the b-values, the proportions of unmethylated, hemi-methylated and methylated CpG sites were not significantly different among the three patients (Fig 4) . Using PCA, the DNA methylation patterns were more similar between the MDS and AML samples of a patient than among the different patients (Fig 4) .
No changes in the DNA methylation from MDS to AML were identified in Patient 4. Patient 6 had a significant decrease in methylation downstream of exon 1 of BAALC at AML compared with MDS; significant increases were identified in the promoter regions of AMT, RUFY1 and PIWIL4, the 3'UTR of NICN1 and the exonic region of FUT4 0·0 0·2 0·4 0·6 0·8 1·0 Beta ( Figure S4) . In Patient 8, we observed a significant decrease in methylation in the promoter region of KIAA0754 and the gene body of MACF1 ( Figure S3 ). The aforementioned genes were assessed for mRNA expression ( Figure S4 ). In Patient 6, all genes, including BAALC, showed a significant reduction of expression at AML compared to MDS: AMT 0Á33-fold change, NICN1 and RUFY1 0Á62-fold, BAALC and FUT4 0Á74-fold, PIWIL4 0Á75-fold. Patient 8, showed significantly reduced expression levels of KIAA0754 at AML compared to MDS (0Á70-fold).
Discussion
The main cause of death among MDS patients is progression to AML (Nachtkamp et al, 2016) . Progression is associated with a cumulative acquisition of mutations and consequent changes in the clonal architecture (Walter et al, 2012 (Walter et al, , 2013 Papaemmanuil et al, 2013; Mossner et al, 2016; Makishima et al, 2017; da Silva-Coelho et al, 2017) . Changes in DNA methylation contribute to AML development (Jiang et al, 2009) . Close monitoring of the genetic and epigenetic features of MDS may therefore provide the unique possibility to adapt therapy strategies earlier and to better understand the biological basis of AML development. In this study, we examined genetic aberrations and the pertinent clonal architectures, as well as DNA methylation patterns during MDS and their changes after progression to AML.
MDS patients preferably harboured mutations in genes encoding proteins functioning in RNA splicing or epigenetic regulation. Mutations in these genes were exclusively present in the major clone, consistent with the occurrence early in disease. In most patients, the VAFs in the major clone were too close to each other to identify a single founder mutation. This reflects the linear evolution due to the growth advantage that each new mutation, gained in the ancestral clone, conveyed to the generated subclone. Distinct subclones could be distinguished from the major clone in only three patients. Mutations in genes involved in RNA splicing or epigenetic regulation have also been identified as frequent and early events in previous studies in MDS and CHIP (Bejar et al, 2012; Papaemmanuil et al, 2013; Kwok et al, 2015; Steensma et al, 2015; Mossner et al, 2016) .
No AML developed that was genetically independent of a pre-existing MDS clone. At the time of AML diagnosis, most patients had gained one new mutation. Newly acquired mutations occurred almost exclusively in genes encoding proteins involved in signal transduction. Our observations are in line with previous studies demonstrating that mutations in these genes are secondary events, primarily associated with more advanced disease stage or transformation (Badar et al, 2015; Mossner et al, 2016; Makishima et al, 2017; da Silva-Coelho et al, 2017) . CSF3R mutations have not yet been described as transforming event in MDS. They coincide with CEBPA mutations in AML (as in our patient) (Maxson et al, 2016) , occur in chronic neutrophilic leukaemia in which they may mediate responsiveness to ruxolitinib (Maxson et al, 2013) , and are the transforming event in severe congenital neutropenia (Germeshausen et al, 2008) .
In three patients, we were able to study the changes in the clonal architectures under treatment. For example, in Patient 7, the size of the del(5q) MDS clone decreased under lenalidomide. Previous studies also observed that lenalidomide in del(5q) MDS patients can reduce clone sizes, although a complete molecular remission was not achieved (Mossner et al, 2016; da Silva-Coelho et al, 2017) . During lenalidomide treatment, the patients, as was the case in our study, displayed a re-occurrence of initial founder clones or emergence of new clones with additional genetic alterations (Mossner et al, 2016; da Silva-Coelho et al, 2017) .
In Patient 3, who received DAC (days 1-5 of each course) and ATRA (days 6-28), no clonal changes were observed at day 15. This correlates well with the clinical observation that several courses of DAC are necessary to achieve the best response. The VAF reduction of the RUNX1 p.S141fs and FLT3-TKD mutations after 6 DAC courses that we observed was most probably due to the emergence of a FLT3-ITD rather than a direct treatment effect. Incomplete mutation clearance and variable sensitivity of clones to treatment was also observed in AML patients treated with DAC according to the 10-day schedule (Welch et al, 2016) . Secondary resistance mechanisms to HMAs have not yet been established. If the gain of mutations in signalling pathways is one mechanism and considering that acquisition of these mutations is part of the natural disease course, then this raises the question as to what extent HMAs impact their occurrence.
The changes in mutations and clonal architecture under MDS progression or treatment support close genetic monitoring of patients in order to allow an early re-evaluation of therapeutic strategies. In Patient 3, for example, the emergence of FLT3 mutated clones under DAC treatment may have led to a switch or the addition of a tyrosine kinase inhibitor (Ravandi et al, 2013; Strati et al, 2015) . However, it currently remains to be established in prospective trials to what extent early recognition of the transforming event and adjustments in patientcare favourably impact survival or quality of life.
Three patients each showed multiple mutations in the same gene. This can be observed in up to 30% of AML patients, but is still poorly understood (The Cancer Genome Atlas Research Network, 2013; Bolli et al, 2015; Mossner et al, 2016; Sun et al, 2017) . The number of patients and genes affected are probably higher than the studies available to date suggest, because many of these mutations may be present at low VAFs only. Our sequencing data showed that in two patients, the mutations probably resided in different clones. Of these, Patient 8 had acquired a WT1 p.K399fs mutation in an NRAS p.G13D mutated clone during MDS. This clone had expanded by the time of AML diagnosis, which was accompanied by the emergence of further subclones with mutations in NRAS and WT1. Single-cell sequencing verified the co-occurrence of the mutations in the clones and thereby our conclusions on clonal evolution.
The existence of multiple clones with mutations in identical genes raises the question as to whether a fertile ground promotes the acquisition or selection of clones with a specific genotype. The existence of such a fertile ground has not yet been established, but hypothetically could be related intracellularly to genetic or epigenetic features of a common ancestral clone or extracellularly to distinct characteristics of the microenvironment. Improved knowledge could help us to understand the disease biology and may provide a basis for early, clone-directed therapeutic interventions.
In addition to the genetics, we analysed DNA methylation profiles in patients in whom MDS progression could not be assigned to the acquisition of a new mutation, and we observed changes between MDS and AML in two patients. For 7 of 8 genes, methylation changes were associated with changes in the expression of the mRNA isoforms that we assessed. Among these genes were BAALC, AMT, PIWIL4 and FUT4, all of which have been shown to be differentially expressed or methylated in cancer (Stirewalt et al, 2008; Schwind et al, 2010; Kim et al, 2011; Navarro et al, 2015) . Our data suggest that DNA methylation of individual genes can occur as additional, epigenetic hits during progression of MDS.
We are aware that our study has limitations that impact the possibility of conclusions. Our patient cohort is relatively small and was analysed via panel sequencing. A whole-genome or whole-exome approach in a larger cohort of patients would have probably allowed the identification of further mutations, also in patients in which we were not able to identify new mutations upon MDS progression. Moreover, it may have allowed a more sensitive detection of CNVs than our array-based approach. In addition, our sequencing depth did not allow us to reliably identify very small subclones. However, our study is one of only a few that report NGS data from serial samples of MDS patients progressing to AML and under treatment (Walter et al, 2012; Mossner et al, 2016; Makishima et al, 2017; da Silva-Coelho et al, 2017) . In addition, our study is characterized by rigorous validation of the NGS data through orthogonal methods and the complementation by results obtained from single-cell sequencing and DNA methylation profiling.
Overall, our analyses enabled us to recapitulate the preferential occurrence of mutations in genes implicated in RNA splicing or epigenetic regulation in MDS, the association of clonal outgrowth at MDS progression with the acquisition of a mutation in a gene involved in signal transduction, and the shift or emergence of clones under treatment of MDS or AML. In patients without apparent gain of mutations causing MDS progression, we observed changes in DNA methylation and in the expression of individual genes. The occurrence or acquisition of multiple mutations in the same genes in different clones, suggest the existence of a fertile ground that promotes selection or acquisition of these clones. Future studies that prospectively investigate the impact of a close genetic monitoring on outcomes in MDS and AML, and that further characterize the fertile grounds for specific mutations appear warranted.
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